Current Portfolio Companies

Aclipse

Cleancult

CleanCult is a versatile enterprise specialising in gardening services. As one of UCEA’s strategic investments, Cleancult is committed to delivering high-quality services and innovative solutions within its industry. The company’s dedication to excellence and adaptability reflects UCEA’s mission to support ventures that make a positive impact in their respective sectors and communities.

SynPhNe

SynPhNe (Synergistic Physio-Neuro Platform) is a pioneering medtech company transforming the field of neurorehabilitation through intelligent wearable systems. Its proprietary technology enables simultaneous training of the brain and muscles, offering real-time insights and tailored therapy for individuals recovering from strokes, traumatic brain injuries, and neurodegenerative conditions.

As part of UCEA’s strategic investment portfolio, SynPhNe exemplifies our commitment to supporting breakthrough healthcare innovations with global reach. With a growing presence across Asia and North America, SynPhNe is setting new standards in personalized rehabilitation, helping patients regain independence and improve quality of life.

Level E

Level E Research is an Edinburgh-based fintech company specializing in AI-driven investment management solutions. Established in 2018 as a spin-off from the University of Edinburgh’s School of Informatics, the company leverages machine learning, data science, and behavioral economics to develop autonomous investment strategies that surpass traditional human capabilities. In March 2023, Level E Research secured £1.2 million in seed funding from investors including M&G, aiming to enhance its platform’s capabilities and expand its market presence. As part of UCEA’s strategic investment portfolio, Level E Research exemplifies our commitment to supporting innovative financial technologies that drive efficiency and productivity in investment management.

Freedom Bio-sciences

Freedom Biosciences is a clinical-stage biotechnology company dedicated to developing innovative treatments for neuropsychiatric disorders. Founded in 2021 by Dr. John Krystal, Chair of the Department of Psychiatry at Yale University, and entrepreneur Dina Burkitbayeva, the company leverages over two decades of groundbreaking research from Yale University to create therapies that address significant unmet needs in mental health care

At Freedom Biosciences, their mission is to revolutionize the treatment landscape for mental health and substance use disorders by developing safe, effective, and accessible therapies. they focus on enhancing the therapeutic profiles of existing treatments through innovative combination therapies, aiming to provide patients with more sustainable and long-lasting relief

With the support of UCEA’s investment, Freedom Biosciences is poised to accelerate the development and commercialization of groundbreaking therapies, offering new hope to individuals grappling with mental health challenges

BforCure

BforCure is a biotechnology company based in Montreuil, France, specialising in high-speed biosensing solutions for microbial analysis. The company has developed the Chronos™ platform—an ultra-fast real-time PCR system that provides comprehensive microbial mapping at the single-cell level within minutes. BforCure’s technology portfolio includes:

• MPD (Molecular Petri Dish): Enables PCR in gels, providing rapid diagnostics and absolute quantification without relying on standard curves.
• hcPCR (High Content PCR): Increases multiplexing capabilities to detect multiple targets in a single reaction, enhancing diagnostic efficiency.
• FastGene: A microfluidic thermal module that significantly reduces thermal ramping time, ensuring swift temperature transitions during PCR.

 These solutions are designed for deployment at sample collection sites, supporting applications in healthcare, defence, food safety, water quality, and agriculture by delivering rapid, point-of-need diagnostics. With extensive R&D and 29 registered patents, BforCure’s technology is engineered for precise and efficient microbial analysis.

LifeQ

LifeQ is revolutionising health and wellbeing by transforming everyday data into powerful insights that empower you to take control of your health. Based in Georgia, United States, LifeQ leverages advanced computational systems biology and AI-driven algorithms to analyse over 150 physiological biomarkers through cutting-edge wearable devices. This technology not only enables non-invasive disease screening and real-time biometric feedback but also reveals your true biological age with LifeQ BioAge™.

At its core, LifeQ is on a mission to add healthspan to your lifespan—ensuring that every heartbeat, every step, and every moment contributes to a healthier, more vibrant future. Whether you are an individual striving for personalised wellness or a business looking to integrate smart health solutions, LifeQ’s innovative platform is designed to transform data into actionable insights.

Join us as we redefine what it means to live well, empowering you to make smarter, life-enhancing decisions every day.

Graphiant

Graphiant, based in Silicon Valley, specializes in next-generation Edge services. The company has developed the Graphiant Network Edge, an innovative “as-a-Service” solution that connects enterprise WAN, hybrid cloud environments, network edges, customers, and partners. 

The Graphiant Network Edge merges MPLS-like performance, ensuring guaranteed delivery and privacy, with the agility typical of Internet-class services. This allows network architects to rapidly establish enterprise-grade networks that meet the evolving demands of business operations. 

Modern enterprise networks are increasingly complex, incorporating hybrid cloud setups, remote workforce connectivity, edge networks, and IoT devices. These networks traverse diverse digital landscapes that IT lacks ownership, control, and visibility over. As a result, provisioning enterprise-grade networks with the necessary agility has become challenging. MPLS provides robust performance with SLA-level reliability, security, and privacy but is costly and complex to deploy. SD-WAN, while flexible, lacks the robustness for scaling tunnels in modern complex networks. 

Graphiant, led by co-founder Khalid Raza, addresses these challenges with their flagship service, the Graphiant Network Edge. By combining MPLS-grade performance with the agility of Internet-class “as-a-Service” models, Graphiant empowers IT teams to deliver enterprise-grade networks swiftly and effectively. 

Sonder Health Plans

Sonder Health Plans, headquartered in Atlanta, Georgia (United States), specializes in offering Medicare Advantage plans tailored for senior citizens in Georgia. The company was inspired by the need to provide comprehensive and cost-effective health insurance solutions specifically designed for this demographic.  

By focusing exclusively on Georgia, Sonder Health Plans targets a substantial market opportunity driven by an aging population in need of affordable health coverage. Sonder Health Plans operates under a value-based model, delivering Medicare Advantage plans that prioritize client needs. Their approach includes a risk insulation strategy for high-cost members, such as vulnerable individuals, achieved through strategic partnerships with vendors offering fixed-cost contracts.  

This strategy allows Sonder Health Plans to optimize revenue while providing essential coverage to higher-risk individuals, distinguishing them from other health insurers in the market. Their mission is to improve the overall health and well-being of their members, making healthcare simple, personal and affordable by delivering on their commitments. 

VII Health, established in Delaware, US while its parent company VII Group is based in Canada, excels in healthcare omnichannel expertise, offering a customer engagement workspace. This platform enhances life sciences by optimizing, personalizing, and broadening AI-driven customer interactions, allowing individuals to access the personal health information of their family members.

It aims to revolutionize patient support and engagement, spanning from disease prevention to treatment management, through tailored and culturally adapted, multilingual solutions. VIIHealth employs a technology-driven service model, utilizing its proprietary AI and personalized video capabilities to enhance customer engagement for healthcare companies. Its primary revenue streams consist of subscription-based digital therapeutic solutions, fee-for-service video content creation and messaging campaigns, and revenue-sharing models for reimbursable digital health products.

By integrating advanced technology with extensive healthcare expertise, VIIHealth strives to revolutionize the interaction between life sciences firms, physicians, patients, and other stakeholders, leading to better outcomes and improved economic efficiency. 

T45

T45 Labs, based in Santa Clara, California, is a medical technology incubator focused on developing minimally invasive technologies that target large addressable markets in the cardiovascular sector. To minimize clinical and commercial risks, T45 Labs pursues a fast-follower strategy to provide higher returns over a shorter period. T45 Fund I is a direct investment vehicle into the portfolio companies of T45 Labs to support the companies’ Series A and Series B financing rounds.

T45 Labs and T45 Fund I leverage a team of accomplished executives and seasoned engineers with numerous years of experience in medical technology investments and development.

UCEA has committed to an investment in T45 Fund I and looks forward to the opportunity to support its impressive portfolio of companies through co-investment in the future.

VahatiCor – developer of a coronary flow reducer for the treatment for angina, due to obstructive and non-obstructive coronary artery disease and heart failure.
NuevoSono – developer of an advanced ultrasound imaging tool for use in minimally invasive surgery.
Advanced NanoTherapies – drug coated balloon technology, licensed from the Clevland Clinic, for the treatment of coronary and peripheral artery disease.
ReCava Medical – device for heart failure management, modulating blood flow to the heart and kidneys.

Intuition Robotics

Intuition Robotics is a pioneering company based in Israel, led by the visionary CEO, Dor Skuler. Intuition Robotics specializes in providing AI-driven companionship solutions for older adults aged 65+ in Central and North America.

With a focus on leveraging artificial intelligence to enhance the lives of older adults, Intuition Robotics is at the forefront of revolutionizing the way we approach companionship and support for seniors. UCEA is impressed by their innovative approach and the positive impact their technology is making in the lives of older individuals.

As an investor, UCEA is excited to support Intuition Robotics in their mission to provide personalized and meaningful companionship solutions that positively impact the daily lives of older adults. We believe in the company’s vision and the value they bring to the aging population, and we look forward to witnessing their continued growth and success in the future.

Bolt

Bolt OS is the next generation immersive (functions include chatting, sharing, donating and purchasing) television ecosystem. Bolt provides content creators of all sizes with the platform and tools to create an immersive experience for smart televisions and other connected devices. Our tools give content creators the freedom to decide the best commercial model to suit their needs ranging from advertising led to operating subscription based models, to issuing their own digital tokens or even offering e-commerce/product sales options, to support their content creation.Viewers enjoying content on the Bolt platform also stand to benefit from being rewarded for engaging with content (including advertising messages) that they are viewing.

The Bolt OS ecosystem incorporates the Bolt+ content platform, the BoltX wallet and marketplace and BoltChain (Bolt’s proprietary blockchain). Bolt already has major global partners ranging from content owners, to smart television brands to payment/e-commerce service providers) including Bloomberg, HiSense/Vidaa, Vizio-Walmart, Manchester City, Real Madrid amongst many other significant international brands. The Bolt+ platform already has more than ten million installs and is poised for the next stage of growth in 2024. The business is profit generating and is on a strong growth curve.

KadenceBio

Kadence Bio is a clinical stage biopharmaceutical company developing novel therapeutics focused on men’s health and mental health conditions. They recently obtained regulatory clinical approvals (US IND, UK CTA) and have initiated Phase 1 human trials to assess the safety and pharmacokinetics of the lead product. Their lead product candidate, KH-001, is being developed as the first FDA-approved treatment for premature ejaculation, a condition that impacts up to 20% of men. Premature ejaculation has no FDA-approved therapies currently available.

KH-001 is a potent, selective, and rapid-acting serotonin transporter inhibitor intended for on-demand use prior to intercourse. In preclinical studies, KH-001 demonstrated dose-dependent efficacy in delaying ejaculation in a validated animal model, along with a favorable safety profile. Kadence Bio has an open IND with the FDA and initiated first-in-human Phase 1 studies in November 2023. With FDA approval, KH-001 is estimated to have peak global sales potential of $2.5-4 billion per year.

In addition to KH-001 for premature ejaculation, Kadence Bio is developing a pipeline of proprietary kanna alkaloid-based compounds for rapid-acting treatment of mood disorders like anxiety and depression.

The goal is to do for premature ejaculation what Viagra did to revolutionize erectile dysfunction treatment. The team of repeat founders are raising an insider-led, pre-Series A convertible note, that is already half-filled.

Chakra Growth Capital

Chakra Growth Fund is a fund advancing cleantech and alternative energy solutions uniquely tailored for Indian communities’ needs. Rather than prioritizing investments maximizing financial returns alone, Chakra partners with Indian tech enterprises striving for positive local impact alongside global influence. Their patient funding model empowers companies to benefit society and the planet while still achieving profitability. We chose to invest because Chakra’s emphasis on responsible innovation mirrors our own values.

Additionally, Chakra Fund II, the latest vehicle from Riso Capital building on their successful first fund. With Fund I generating results of 2.7x returns and 107% IRR, Fund II aims to scale up by targeting more mature Indian companies ready for rapid expansion capital, aiming for 5-7x returns. Areas of focus include electric mobility, agriculture technology, battery tech and more – strategic sectors riding the momentum of India’s development. With our emerging market investment experience and Riso’s results and pipeline, we see Fund II as a compelling opportunity to support India’s continued equitable growth.

Chakra has an impressive portfolio of companies that we can support through co-investment. These companies include:
1. Altergo – Provides performance insights for electric vehicles and energy storage systems.
2. Ambee – Delivers real-time pollution and emissions insights to reduce climate change risks.
3. SupplyNote – Facilitates supply chain operations and data insights for retailers, service providers, and suppliers.

As the world’s fastest-expanding major economy, India presents vast possibilities in EV, battery technology, agri-tech and beyond. We invested in Chakra based on Riso’s proven capacity to identify winners in this explosive environment and accelerate their impact.

One Drives

OpenDrives was founded in 2011 to provide innovative software solutions for managing and storing data across diverse IT environments, including on-premises and multi-cloud. Their flexible and scalable architecture enables media companies to easily handle massive video files. By integrating disparate systems, OpenDrives allows seamless data movement to wherever it is needed, reducing reliance on any one hardware vendor.

We invested in OpenDrives because of their proven track record in meeting the demanding broadcast workflows of major global events, for the 2022 FIFA World Cup, OpenDrives enabled Fox Sports’ coverage to leverage lightning-fast technology. With marquee US sports and media clients such as Fox News, NFL, and Madison Square Garden, OpenDrives has demonstrated the ability to support top-tier organizations.

Given OpenDrives’ successes in the US, we believe there is significant potential to expand their footprint internationally. Our expertise in both European and UK sports and technology markets can facilitate OpenDrives’ entry and growth in these regions. With Joao as the brand ambassador, we can support OpenDrives fully in their expansion of key clients, especially given their agility, and scalability as a provider of data management for large global events. Through our relationships and their product, we are working proactively with OpenDrives’ on additions to their international sales strategy, where we aim to collectively drive rapid expansion into Europe and the UK.

Amlo Biosciences

Rather than taking a passive role, we pursue an active investment strategy aimed at amplifying the positive impact of our portfolio companies. For example, our Chairman recently joined the Board of Directors of AMLO Biosciences, one of our investments focused on expanding access to early cancer screening. He guides commercialization as AMLO looks to bring its potentially life-saving diagnostic solutions to more high-risk populations in Australia, New Zealand and beyond.

With skin cancer and melanoma rates dangerously high in these countries, we believe AMLO’s innovations could have immense life-saving potential through early detection. Yet making such screening ubiquitously available requires navigating complex regulatory systems. Leveraging decades of healthcare investment experience, we are keen on leveraging time, expertise and networks to help expedite AMLO’s global expansion. Our goal is ensuring equitable delivery of AMLO’s tests to the many communities worldwide where earlier cancer diagnosis can dramatically improve survival outcomes.

Additionally, our team is actively utilizing our extensive European relationships and connections to facilitate AMLO’s vital R&D partnerships across the EU. We take an hands-on approach to linking AMLO with major cancer research hubs where we have the relationships to accelerate its product development and clinical trials. We pursue these active measures because we share AMLO’s mission – not just seeking returns, but seeking to save lives by expanding access to early screening globally.